STATCenter·
STAT+: Akeso and Summit’s ivonescimab extends survival in squamous cell lung cancer
A lung cancer drug developed in China was a highlight of ASCO but doctors want to see follow-up in a more diverse population.
Read at STAT →
Health · 1 sources covering this
STAT+: Akeso and Summit’s ivonescimab extends survival in squamous cell lung cancer
A lung cancer drug developed in China was a highlight of ASCO but doctors want to see follow-up in a more diverse population.
Coverage spectrum
0 L · 1 C · 0 R
How 1 sources are covering this
Embed this bias spectrum on your site
Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.
<iframe src="https://statesidedaily.com/embed/cluster/3effc63aa0692a75038a5bdb7b204e969e189252" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="STAT+: Akeso and Summit’s ivonescimab extends survival in squamous cell lung cancer"></iframe>
